Case number 1:22-cv-01215
Intercept Pharmaceuticals, Inc. v. Zenara Pharma Private Limited > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 6, 2024 | 103 | PROPOSED CONSENT JUDGMENT by Intercept Pharmaceuticals, Inc.. (Tigan, Jeremy) (Entered: 03/06/2024) (3) |
| Mar 6, 2024 | 104 | CONSENT JUDGMENT. Signed by Judge Maryellen Noreika on 3/6/2024. ***Civil Case Terminated*** (dlw) (Entered: 03/06/2024) (3) |
| Mar 6, 2024 | 105 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (Attachments: # 1 Consent Judgment)(mdb) (Entered: 03/06/2024) (0) |
| Mar 1, 2024 | 102 | REDACTED VERSION of 99 Letter by Intercept Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)(Tigan, Jeremy) (Entered: 03/01/2024) (0) |
| Feb 26, 2024 | 100 | ORAL ORDER re 99 Letter - Having reviewed the parties' letter and Proposed Amended Scheduling Order, IT IS HEREBY ORDERED that Plaintiffs' proposed deadlines are adopted up to the Markman hearing. The Markman hearing shall be reset for 10/7/2024 at 2:00 p.m. Daubert motions must be filed on or before 1/6/2025 and shall be briefed in accordance with the Local Rules. The Court will not move the Pretrial Conference and Trial dates. The parties shall file an amended [Proposed] Order Amending Scheduling Order incorporating these dates and using this guidance. ORDERED by Judge Maryellen Noreika on 2/26/2024. (dlw) (Entered: 02/26/2024) (0) |
| Feb 26, 2024 | 101 | NOTICE OF SERVICE of Plaintiff's Responses and Objections to Defendant's Fifth Set of Requests for Production (No. 37) filed by Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 02/26/2024) (3) |
| Feb 23, 2024 | 99 | [SEALED] Letter to The Honorable Maryellen Noreika from Jeremy A. Tigan regarding case schedule. (Attachments: # 1 Exhibit A)(Tigan, Jeremy) (Entered: 02/23/2024) (0) |
| Feb 21, 2024 | 98 | NOTICE OF SERVICE of Plaintiff's Responses and Objections to Defendant's First Set of Requests for Admission (Nos. 1-37) filed by Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 02/21/2024) (3) |
| Feb 8, 2024 | 97 | NOTICE OF SERVICE of Plaintiff's Responses and Objections to Defendant's Fourth Set of Interrogatories (Nos. 14-16) filed by Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 02/08/2024) (3) |
| Jan 30, 2024 | 94 | STIPULATION and [Proposed] Order to Amend Case Caption by Intercept Pharmaceuticals, Inc.. (Tigan, Jeremy) (Entered: 01/30/2024) (2) |
| Jan 30, 2024 | 95 | SO ORDERED re 94 Stipulation and Order to Amend Case Caption. Party Intercept Pharma Europe Limited terminated. Attorney Lucinda Cole Cucuzzella; Priscilla G. Dodson; Jeffrey B. Elikan; Daniel Farnoly; Jia Hui Jiang; Megan P. Keane; Laura Marie Martin; Christopher N. Sipes; Eric R. Sonnenschein; Jeremy A. Tigan; Alexander Trzeciak; Douglas A. Behrens and Jack B. Blumenfeld terminated as to this Plaintiff. Signed by Judge Maryellen Noreika on 1/30/2024. (dlw) (Entered: 01/30/2024) (2) |
| Jan 30, 2024 | 96 | Amended Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AlfaSigma S.p.A. for Intercept Pharmaceuticals, Inc. filed by Intercept Pharmaceuticals, Inc.. (Tigan, Jeremy) (Entered: 01/30/2024) (2) |
| Jan 25, 2024 | 93 | NOTICE OF SERVICE of Defendant Zenara's Fifth Set of Requests for Production to Plaintiffs (No. 37) filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 01/25/2024) (2) |
| Jan 24, 2024 | 92 | Official Transcript of Phone Conference held on 1/12/2024 before Judge Laura D. Hatcher. Court Reporter/Transcriber Bobbie J. Shanfelder,Email: Bobbie_Shanfelder@paed.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 2/14/2024. Redacted Transcript Deadline set for 2/26/2024. Release of Transcript Restriction set for 4/23/2024. (apk) (Entered: 01/24/2024) (28) |
| Jan 23, 2024 | 91 | NOTICE to Take Deposition of Richard Lancaster filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 01/23/2024) (3) |
| Jan 22, 2024 | 89 | NOTICE OF SERVICE of Defendant Zenara's First Set of Requests for Admission (Nos. 1-37) filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 01/22/2024) (2) |
| Jan 22, 2024 | 90 | NOTICE OF SERVICE of (1) Defendant's Objections and Responses to Plaintiffs' First Set of Requests for Admission (Nos. 1-30) and (2) Defendant's Objections and Responses to Plaintiffs' Third Set of Interrogatories (Nos.16-19) filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 01/22/2024) (2) |
| Jan 19, 2024 | 86 | NOTICE of Subpoenas by Zenara Pharma Private Limited (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Schladweiler, Benjamin) (Entered: 01/19/2024) (0) |
| Jan 19, 2024 | 87 | NOTICE OF SERVICE of Defendant Zenara's Objections and Responses to Plaintiffs' Notice of Deposition Under Fed. R. Civ. P. 30(B)(6) filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 01/19/2024) (2) |
| Jan 19, 2024 | 88 | NOTICE of Subpoenas: (1) Subpoena to Testify at a Deposition to Mark Pruzanski, M.D. and (2) Subpoena to Produce Documents, Information or Objects to Mark Pruzanski, M.D. by Zenara Pharma Private Limited (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Schladweiler, Benjamin) (Entered: 01/19/2024) (0) |
| Jan 12, 2024 | 85 | ORAL ORDER: For the reasons detailed during the teleconference on January 12, 2024, Zenara Pharma Private Limiteds motion (D.I. 70) is GRANTED-IN-PART with respect to its improper reissue defense, and Intercept Pharmaceuticals, Inc.s motion (D.I. 71) is GRANTED-IN-PART and DENIED-IN-PART. The transcript of the January 12, 2024 hearing contains the Court's rationale and further details regarding the Court's ruling. Ordered by Judge Laura D. Hatcher on 1/12/24. (kjk) ( Court Reporter - Bobbie Shanfelder ) Modified on 1/12/2024 (kjk). (Entered: 01/12/2024) (0) |
| Jan 9, 2024 | 82 | NOTICE to Take Deposition of Mark Pruzanski, M.D. filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 01/09/2024) (3) |
| Jan 9, 2024 | 83 | NOTICE of Defendant's Notice of Subpoena by Zenara Pharma Private Limited (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Schladweiler, Benjamin) (Entered: 01/09/2024) (0) |
| Jan 9, 2024 | 84 | NOTICE OF SERVICE of (1) Defendant Zenara Pharma Private Limited's Fourth Set of Interrogatories (Nos. 14-16) and (2) Defendant Zenara Pharma Private Limited's First Notice of Deposition of Plaintiffs Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 01/09/2024) (2) |
| Jan 8, 2024 | 79 | MOTION for Pro Hac Vice Appearance of Attorney Eric R. Sonnenschein, Priscilla G. Dodson, Alexander Trzeciak, Daniel Farnoly, Laura Marie Martin, and Jia Hui Jiang - filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc.. (Tigan, Jeremy) (Entered: 01/08/2024) (9) |
| Jan 8, 2024 | 80 | Pro Hac Vice Fee - Credit Card Payment received for Eric R. Sonnenschein, Priscilla G. Dodson, Alexander Trzeciak, Daniel Farnoly, and Laura Marie Martin. ( re 79 MOTION for Pro Hac Vice Appearance of Attorney Eric R. Sonnenschein, Priscilla G. Dodson, Alexander Trzeciak, Daniel Farnoly, Laura Marie Martin, and Jia Hui Jiang )( Payment of $ 250, receipt number ADEDC-4308900).(Tigan, Jeremy) (Entered: 01/08/2024) (0) |
| Jan 8, 2024 | 81 | Pro Hac Vice Fee - Credit Card Payment received for Jia Hui Jiang. ( re 79 MOTION for Pro Hac Vice Appearance of Attorney Eric R. Sonnenschein, Priscilla G. Dodson, Alexander Trzeciak, Daniel Farnoly, Laura Marie Martin, and Jia Hui Jiang )( Payment of $ 50, receipt number ADEDC-4308904).(Tigan, Jeremy) (Entered: 01/08/2024) (0) |
| Jan 5, 2024 | 76 | REDACTED VERSION of 71 Letter by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc.. (Attachments: # 1 Exs. A-J)(Tigan, Jeremy) (Entered: 01/05/2024) (0) |
| Jan 5, 2024 | 77 | Letter to Magistrate Judge Hatcher from Benjamin J. Schladweiler regarding Defendant's Responsive letter Opposing Plaintiffs and Non-Parties Dr.s Elfiri and Kiselgof's Motion to Quash Subpoenas. (Attachments: # 1 Exhibit 1)(Schladweiler, Benjamin) (Entered: 01/05/2024) (0) |
| Jan 5, 2024 | 78 | Letter to The Honorable Laura D. Hatcher from Jeremy A. Tigan regarding Intercept's Opposition to Zenara's Motion to Compel Discovery - re 64 Oral Order,,,, 70 Letter,. (Attachments: # 1 Exhibits A-J)(Tigan, Jeremy) (Entered: 01/05/2024) (0) |
| Jan 2, 2024 | 73 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendant's Third Set of Interrogatories (No. 13) - filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 01/02/2024) (3) |
| Jan 2, 2024 | 74 | MOTION for Pro Hac Vice Appearance of Attorney Catharina J. Chin Eng - filed by Zenara Pharma Private Limited. (Attachments: # 1 Certification of Catharina J. Chin Eng)(Schladweiler, Benjamin) (Entered: 01/02/2024) (0) |
| Jan 2, 2024 | 75 | Pro Hac Vice Fee - Credit Card Payment received for Catharina J. Chin Eng. ( re 74 MOTION for Pro Hac Vice Appearance of Attorney Catharina J. Chin Eng )( Payment of $ 50, receipt number ADEDC-4305058).(Schladweiler, Benjamin) (Entered: 01/02/2024) (0) |
| Dec 29, 2023 | 70 | Letter to Magistrate Judge Hatcher from Benjamin J. Schladweiler regarding motion to compel Plaintiffs to respond to discovery requests. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Proposed Order)(Schladweiler, Benjamin) (Entered: 12/29/2023) (0) |
| Dec 29, 2023 | 71 | [SEALED] Letter to The Honorable Laura D. Hatcher from Jeremy A. Tigan regarding Discovery Disputes - re 64 Oral Order,,,,. (Attachments: # 1 Exs. A-J)(Tigan, Jeremy) (Entered: 12/29/2023) (0) |
| Dec 29, 2023 | 72 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendant's Fourth Set of Requests for Production (Nos. 34-36) - filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 12/29/2023) (3) |
| Dec 21, 2023 | 66 | NOTICE OF SERVICE of (1) Plaintiffs' First Set of Requests for Admission to Defendant Zenara (Nos. 1-30); (2) Plaintiffs' Third Set of Interrogatories to Zenara (Nos. 16-19); and (3) Plaintiffs' Notice of Deposition to Defendant Zenara Under Fed. R. Civ. P. 30(b)(6) filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 12/21/2023) (3) |
| Dec 21, 2023 | 67 | NOTICE to Take Deposition of Mahaboob Dowla on January 30, 2024 filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 12/21/2023) (3) |
| Dec 21, 2023 | 68 | NOTICE to Take Deposition of Bhaskar Reddy on February 7, 2024 filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 12/21/2023) (3) |
| Dec 21, 2023 | 69 | NOTICE to Take Deposition of Praveen Kumar on February 13, 2024 filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 12/21/2023) (3) |
| Dec 19, 2023 | 64 | ORAL ORDER. The Court has reviewed the parties' Joint Motion for Teleconference to Resolve Discovery Disputes (D.I. 63). A teleconference is scheduled for Friday, January 12, 2024 at 10:00 AM Eastern Time before Judge Laura D. Hatcher. By no later than Friday, December 29, 2023, any party seeking relief shall file with the Court a letter not to exceed three pages in no less than 12-point font outlining the issues in dispute and that party's position on those issues. By no later than Friday, January 5, 2024, any party opposing the application for relief may file a letter not to exceed three pages in no less than 12-point font outlining its opposition. Counsel is reminded to provide courtesy copies. Counsel shall send dial-in information directly to the Court no later than 24 hours prior to the hearing using the following e-mail address: keith_kincaid@ded.uscourts.gov. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event cancel the conference. Signed by Judge Laura D. Hatcher on December 19, 2023. (Entered: 12/19/2023) (0) |
| Dec 19, 2023 | 65 | NOTICE OF SERVICE of (1) Plaintiffs' and Non-Party Dr. Eugenia (Jane) Kiselgof's Joint Responses and Objections to Defendant's Subpoena to Produce Documents; and (2) Plaintiffs' and Non-Party Dr. Ivor Elrifi's Joint Responses and Objections to Defendant's Subpoena to Produce Documents filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 12/19/2023) (3) |
| Dec 18, 2023 | 63 | Joint MOTION for Teleconference to Resolve Discovery Disputes re 62 Oral Order,, - filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc.. (Tigan, Jeremy) (Entered: 12/18/2023) (2) |
| Dec 14, 2023 | 62 | ORAL ORDER - Consistent with the Scheduling Order, the parties contacted Chambers to request a teleconference date for competing discovery disputes, IT IS HEREBY ORDERED that these disputes are referred to Magistrate Judge Hatcher. The parties are directed to file Magistrate Judge Hatcher's "Motion for Teleconference to Resolve Discovery/Protective Order Disputes" which can be found at https://www.ded.uscourts.gov/judge/magistrate-judge-laura-d-hatcher, forms. ORDERED by Judge Maryellen Noreika on 12/14/2023. (dlw) (Entered: 12/14/2023) (0) |
| Dec 12, 2023 | 60 | NOTICE OF SERVICE of Plaintiffs' Preliminary Construction and Identification of Intrinsic Evidentiary Support filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 12/12/2023) (3) |
| Dec 12, 2023 | 61 | NOTICE OF SERVICE of Defendant's Proposed Preliminary Construction of Claim Terms and Identification of Supporting Intrinsic Evidence for the RE48,286 Patent filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 12/12/2023) (2) |
| Dec 6, 2023 | 59 | NOTICE of Subpoena by Zenara Pharma Private Limited (Schladweiler, Benjamin) (Entered: 12/06/2023) (3) |
| Dec 1, 2023 | 56 | NOTICE OF SERVICE of Defendant Zenara Pharma Private Limited's Initial Identification of Proposed Claim Terms for Claim Construction for the RE48,286 Patent filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 12/01/2023) (2) |
| Dec 1, 2023 | 57 | NOTICE OF SERVICE of Defendant Zenara Pharma Private Limited's Third Set of Interrogatories (No. 13) filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 12/01/2023) (2) |
| Dec 1, 2023 | 58 | NOTICE OF SERVICE of Plaintiffs' Identification of Proposed Terms for Construction filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 12/01/2023) (3) |
| Nov 29, 2023 | 55 | NOTICE OF SERVICE of Defendant Zenara's Fourth Set of Requests for Production to Plaintiffs (Nos. 34-36) filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 11/29/2023) (2) |
| Nov 21, 2023 | 54 | NOTICE OF SERVICE of Defendant's Initial Invalidity Contentions for U.S. Patent No. RE48,286 filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 11/21/2023) (2) |
| Oct 13, 2023 | 53 | NOTICE OF SERVICE of (1) Plaintiffs' Responses and Objections to Defendant's Second Set of Interrogatories (No. 12) and (2) Plaintiffs' Responses and Objections to Defendant's Second Set of Requests for Production (Nos. 27-33) filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 10/13/2023) (3) |
| Oct 6, 2023 | 52 | NOTICE OF SERVICE of Plaintiffs' Initial Infringement Contentions Regarding Zenara's Infringement of U.S. Patent No. RE48,286 filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 10/06/2023) (3) |
| Sep 15, 2023 | 50 | NOTICE OF SERVICE of Defendant Zenara Pharma Private Limited's Amended Initial Disclosures and Paragraph 3 Disclosures filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 09/15/2023) (2) |
| Sep 15, 2023 | 51 | NOTICE OF SERVICE of (1) Plaintiffs' Amended Initial Disclosures Pursuant to Rule 26(a)(1); (2) Plaintiffs' Amended Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery; and (3) Plaintiffs' Amended Initial Disclosures Identifying Defendant's Accused Products and Plaintiffs' Asserted Patents filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 09/15/2023) (3) |
| Sep 14, 2023 | 49 | NOTICE OF SERVICE of (1) Defendant Zenara Pharma Private Limited's Second Set of Interrogatories to Plaintiffs (No. 12), and (2) Defendant Zenara Pharma Private Limited's Third Set of Requests for Production to Plaintiffs (Nos. 27-33) filed by Zenara Pharma Private Limited.(Delcollo, Renee) (Entered: 09/14/2023) (2) |
| Aug 21, 2023 | 48 | Amended Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Intercept Pharmaceuticals, Inc. for Intercept Pharma Europe Limited; Other Affiliate BlackRock, Inc. for Intercept Pharmaceuticals, Inc. filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc.. (Tigan, Jeremy) (Entered: 08/21/2023) (2) |
| Aug 15, 2023 | 46 | STIPULATION and [Proposed] Order to Consolidate by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc.. (Tigan, Jeremy) (Entered: 08/15/2023) (4) |
| Aug 15, 2023 | 47 | SO ORDERED re (46 in 1:22-cv-01215-MN, 10 in 1:23-cv-00714-MN) Stipulation and Order to Consolidate. These cases are consolidated for all purposes. Set/Reset Scheduling Order Deadlines - Amended Pleadings due by 1/12/2024. Fact Discovery completed by 2/23/2024. Opening Expert Reports due by 8/23/2024. Rebuttal Expert Reports due by 9/27/2024. Reply Expert Reports due by 10/25/2024. Expert Discovery due by 11/22/2024. Joinder of Parties due by 1/12/2024. Claim Construction Opening Brief served by 5/3/2024. Claim Construction Answering Brief served by 5/24/2024. Claim Construction Reply Brief served by 6/11/2024. Claim Construction Surreply Brief served by 6/25/2024. Joint Claim Construction Brief filed by 7/1/2024. A Markman Hearing is set for 7/31/2024 at 10:00 AM in Courtroom 4A before Judge Maryellen Noreika., A Pretrial Conference is set for 3/11/2025 at 04:30 PM in Courtroom 4A before Judge Maryellen Noreika. A 5-day Bench Trial is set for 3/17/2025 at 09:00 AM in Courtroom 4A before Judge Maryellen Noreika. Signed by Judge Maryellen Noreika on 8/15/2023. (dlw) (Entered: 08/15/2023) (4) |
| Jul 12, 2023 | 45 | STIPULATION and [Proposed] Order Regarding Claim Construction by Zenara Pharma Private Limited. (Delcollo, Renee) (Entered: 07/12/2023) (3) |
| Jul 3, 2023 | 44 | ORAL ORDER: The Telephone Conference re 41 Stipulation and [Proposed] Order Regarding Claim Construction is RESCHEDULED for 7/6/2023 at 4:00 PM before Judge Maryellen Noreika. ORDERED by Judge Maryellen Noreika on 7/3/2023. (mdb) (Entered: 07/03/2023) (0) |
| Jun 28, 2023 | 43 | ORAL ORDER Setting Teleconference re 41 Stipulation and [Proposed] Order Regarding Claim Construction - IT IS HEREBY ORDERED that a telephone Conference is set for 7/3/2023 at 02:00 PM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 6/28/2023. (dlw) (Entered: 06/28/2023) (0) |
| Jun 26, 2023 | 42 | NOTICE OF SERVICE of Plaintiffs' Supplemental Preliminary Constructions and Identification of Intrinsic Evidentiary Support filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 06/26/2023) (3) |
| Jun 23, 2023 | 41 | STIPULATION and [Proposed] Order Regarding Claim Construction by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc.. (Tigan, Jeremy) (Entered: 06/23/2023) (3) |
| Jun 20, 2023 | 40 | STIPULATION TO EXTEND TIME for the parties to meet and confer regarding claim construction (D.I. 16, Exhibit A) to July 7, 2023 - filed by Zenara Pharma Private Limited. (Delcollo, Renee) (Entered: 06/20/2023) (1) |
| Jun 14, 2023 | 39 | NOTICE OF SERVICE of (1) Defendant's Objections and Responses to Plaintiffs' Second Set of Interrogatories, and (2) Defendant's Objections and Responses to Plaintiffs' Second Set of Requests for Production of Documents and Things filed by Zenara Pharma Private Limited.(Delcollo, Renee) (Entered: 06/14/2023) (2) |
| Jun 13, 2023 | 37 | NOTICE OF SERVICE of Defendant's Proposed Claim Constructions and Intrinsic Evidence filed by Zenara Pharma Private Limited.(Delcollo, Renee) (Entered: 06/13/2023) (2) |
| Jun 13, 2023 | 38 | NOTICE OF SERVICE of Plaintiffs' Preliminary Constructions and Identification of Intrinsic Evidentiary Support - filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 06/13/2023) (3) |
| Jun 6, 2023 | 36 | NOTICE OF SERVICE of Plaintiffs' Identification of Claim Terms for Construction filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 06/06/2023) (3) |
| Jun 2, 2023 | 35 | NOTICE OF SERVICE of Defendant's Initial Identification of Proposed Claim Terms for Claim Construction and Initial Identification of Indefinite Claim Terms filed by Zenara Pharma Private Limited.(Delcollo, Renee) (Entered: 06/02/2023) (2) |
| May 30, 2023 | 33 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendant's Second Set of Requests for Production (Nos. 11-26) filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 05/30/2023) (3) |
| May 30, 2023 | 34 | NOTICE OF SERVICE of Defendant Zenara Pharma Private Limited's Initial Invalidity Contentions filed by Zenara Pharma Private Limited.(Delcollo, Renee) (Entered: 05/30/2023) (2) |
| May 15, 2023 | 32 | NOTICE OF SERVICE of (1) Plaintiffs' Second Set of Interrogatories to Zenara (Nos. 13-15); and (2) Plaintiffs' Second Set of Requests for Production of Documents and Things to Zenara (Nos. 88-90) filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 05/15/2023) (3) |
| Apr 28, 2023 | 31 | NOTICE OF SERVICE of Defendant Zenara Pharma Private Limited's Second Set of Requests for Production to Plaintiffs (Nos. 11-26) filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 04/28/2023) (2) |
| Apr 17, 2023 | 30 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendant's First Set of Interrogatories (Nos. 1-11) filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 04/17/2023) (3) |
| Apr 14, 2023 | 29 | NOTICE OF SERVICE of Plaintiffs' Initial Infringement Contentions to Zenara filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 04/14/2023) (3) |
| Apr 10, 2023 | 28 | NOTICE OF SERVICE of Defendant Zenara Pharma Private Limited's (1) Objections and Responses to Plaintiffs' First Set of Requests for Production of Documents and Things (Nos. 1-87), and (2) Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-12) filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 04/10/2023) (2) |
| Mar 24, 2023 | 27 | NOTICE OF SERVICE of Plaintiffs' Responses and Objections to Defendant's First Set of Requests for Production (Nos. 1-10) filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 03/24/2023) (3) |
| Mar 16, 2023 | 26 | NOTICE OF SERVICE of Defendant Zenara Pharma Private Limited's First Set of Interrogatories to Plaintiff (Nos. 1-11) filed by Zenara Pharma Private Limited.(Delcollo, Renee) (Entered: 03/16/2023) (2) |
| Mar 9, 2023 | 25 | NOTICE OF SERVICE of (1) Plaintiffs' First Set of Interrogatories to Zenara (Nos. 1-12) and (2) Plaintiffs' First Set of Requests for Production of Documents and Things to Zenara (Nos. 1-87) filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 03/09/2023) (3) |
| Feb 22, 2023 | 24 | NOTICE OF SERVICE of Defendant Zenara Pharma Private Limited's First Set of Requests for Production to Plaintiffs filed by Zenara Pharma Private Limited.(Delcollo, Renee) (Entered: 02/22/2023) (2) |
| Feb 21, 2023 | 23 | STIPULATED PROTECTIVE ORDER. Signed by Judge Maryellen Noreika on 2/21/2023. (dlw) (Entered: 02/21/2023) (20) |
| Feb 17, 2023 | 21 | NOTICE OF SERVICE of Plaintiffs' Initial Disclosures Identifying Defendant's Accused Products and Plaintiffs' Asserted Patents filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 02/17/2023) (3) |
| Feb 17, 2023 | 22 | PROPOSED ORDER -- Proposed Stipulated Protective Order -- by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc.. (Tigan, Jeremy) (Entered: 02/17/2023) (20) |
| Feb 10, 2023 | 20 | STIPULATION TO EXTEND TIME for the parties to submit a proposed protective order for the Court's consideration (D.I. 16, Paragraph 3) to February 17, 2023 - filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc.. (Cucuzzella, Lucinda) (Entered: 02/10/2023) (2) |
| Feb 3, 2023 | 18 | NOTICE OF SERVICE of Defendant Zenara Pharma Private Limited's Initial Disclosures and Paragraph 3 Disclosures filed by Zenara Pharma Private Limited.(Schladweiler, Benjamin) (Entered: 02/03/2023) (2) |
| Feb 3, 2023 | 19 | NOTICE OF SERVICE of (1) Plaintiffs' Initial Disclosures Pursuant to Rule 26(a)(1) and (2) Plaintiffs' Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc..(Tigan, Jeremy) (Entered: 02/03/2023) (3) |
| Feb 1, 2023 | 16 | SCHEDULING ORDER: Joinder of Parties due by 7/14/2023. Amended Pleadings due by 7/14/2023. Fact Discovery completed by 8/4/2023. Opening Expert Reports due by 1/25/2024. Rebuttal Expert Reports due by 2/29/2024. Reply Expert Reports due by 3/28/2024. Expert Discovery due by 5/2/2024. Claim Construction Opening Brief served by 9/29/2023. Claim Construction Answering Brief served by 10/20/2023. Claim Construction Reply Brief served by 11/3/2023. Claim Construction Surreply Brief served by 11/17/2023. Joint Claim Construction Brief filed by 11/28/2023. A Markman Hearing is set for 12/20/2023 at 02:00 PM in Courtroom 4A before Judge Maryellen Noreika. A Pretrial Conference is set for 7/15/2024 at 10:00 AM in Courtroom 4A before Judge Maryellen Noreika. A 5-day Bench Trial is set for 7/22/2024 at 09:00 AM in Courtroom 4A before Judge Maryellen Noreika. Signed by Judge Maryellen Noreika on 2/1/2023. (dlw) (Entered: 02/01/2023) (14) |
| Feb 1, 2023 | 17 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Biophore India Pharmaceuticals Private Ltd. for Zenara Pharma Private Limited filed by Zenara Pharma Private Limited. (Schladweiler, Benjamin) (Entered: 02/01/2023) (1) |
| Jan 27, 2023 | 15 | PROPOSED ORDER // Scheduling Order by Zenara Pharma Private Limited. (Attachments: # 1 Cover Letter to the Honorable Maryellen Noreika)(Cucuzzella, Lucinda) Modified on 1/30/2023 (dlw). (Entered: 01/27/2023) (Main Document) (14) |
| Jan 27, 2023 | 15 | PROPOSED ORDER // Scheduling Order by Zenara Pharma Private Limited. (Attachments: # 1 Cover Letter to the Honorable Maryellen Noreika)(Cucuzzella, Lucinda) Modified on 1/30/2023 (dlw). (Entered: 01/27/2023) (Cover Letter to the Honorable Maryellen Noreika) (1) |
| Jan 24, 2023 | 13 | NOTICE of Appearance by Renee Mosley Delcollo on behalf of Zenara Pharma Private Limited (Delcollo, Renee) (Entered: 01/24/2023) (1) |
| Jan 24, 2023 | 14 | STIPULATION TO EXTEND TIME for the parties to submit a proposed scheduling order pursuant to the Courts December 15, 2022, Oral Order (D.I. 11) to January 27, 2023 - filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc.. (Tigan, Jeremy) (Entered: 01/24/2023) (1) |
| Jan 13, 2023 | 12 | STIPULATION TO EXTEND TIME or the parties to submit a proposed scheduling order pursuant to the Court's December 15, 2022, Oral Order (D.I. 11) to January 24, 2023 - filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc.. (Tigan, Jeremy) (Entered: 01/13/2023) (1) |
| Dec 15, 2022 | 11 | ORAL ORDER - IT IS HEREBY ORDERED that, within thirty (30) days from the date of this Order, the parties shall confer regarding proposed dates in the scheduling order and shall submit a proposed order, which is also consistent with the following guidance. A Bench Trial will be set to begin on 7/22/2024. The parties shall provide final contentions (i.e., final infringement and invalidity contentions, as well as final non-infringement and validity contentions) around the time that fact discovery closes (i.e., several weeks prior to or after the deadline to complete fact discovery) and at least three weeks before Plaintiffs serve their opening claim construction brief. Final contentions shall include a party's contentions under its proposed construction(s), as well as under the opposing construction(s) (if such an alternative contention exists). As such, the parties are encouraged to exchange proposed claim terms and proposed constructions early in the case but in no event later than necessary to allow the parties to include alternative contentions in their final contentions. The joint claim construction chart shall be due one week after the parties have completed their exchange of final contentions, and the joint claim construction brief must be filed at least three weeks before the claim construction hearing. The parties shall leave at least three weeks between the claim construction hearing and the opening of expert discovery. The parties are to use the Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Judge Noreika, Forms), and the parties must include a proposal for the length and timing of trial. If there are disputes or issues that the Court needs to address in the proposed scheduling order, the parties shall direct the Court to the paragraph numbers in which those appear in a cover letter to the Court. ORDERED by Judge Maryellen Noreika on 12/15/2022. (dlw) (Entered: 12/15/2022) (0) |
| Nov 30, 2022 | 10 | MOTION for Pro Hac Vice Appearance of Attorney Christopher Sipes, Jeffrey B. Elikan, Megan Keane and Douglas A. Behrens - filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc.. (Tigan, Jeremy) (Entered: 11/30/2022) (7) |
| Nov 23, 2022 | 9 | MOTION for Pro Hac Vice Appearance of Attorney Dmitry v. Shelhoff, Kenneth S. Canfield, Edward D. Pergament and Julia S. Kim - filed by Zenara Pharma Private Limited. (Attachments: # 1 Text of Proposed Order Proposed Order, # 2 Certification by Counsel to Be Admitted Pro Hac Vice - Dmitry V. Shelhoff, Esq., # 3 Certification by Counsel to Be Admitted Pro Hac Vice - Kenneth S. Canfield, Esq., # 4 Certification by Counsel to Be Admitted Pro Hac Vice - Edward D. Pergament, Esq., # 5 Certification by counsel to Be Admitted Pro Hac Vice - Julia S. Kim, Esq.)(Schladweiler, Benjamin) (Entered: 11/23/2022) (Main Document) (1) |
| Nov 23, 2022 | 9 | MOTION for Pro Hac Vice Appearance of Attorney Dmitry v. Shelhoff, Kenneth S. Canfield, Edward D. Pergament and Julia S. Kim - filed by Zenara Pharma Private Limited. (Attachments: # 1 Text of Proposed Order Proposed Order, # 2 Certification by Counsel to Be Admitted Pro Hac Vice - Dmitry V. Shelhoff, Esq., # 3 Certification by Counsel to Be Admitted Pro Hac Vice - Kenneth S. Canfield, Esq., # 4 Certification by Counsel to Be Admitted Pro Hac Vice - Edward D. Pergament, Esq., # 5 Certification by counsel to Be Admitted Pro Hac Vice - Julia S. Kim, Esq.)(Schladweiler, Benjamin) (Entered: 11/23/2022) (Text of Proposed Order Proposed Order) (1) |
| Nov 23, 2022 | 9 | MOTION for Pro Hac Vice Appearance of Attorney Dmitry v. Shelhoff, Kenneth S. Canfield, Edward D. Pergament and Julia S. Kim - filed by Zenara Pharma Private Limited. (Attachments: # 1 Text of Proposed Order Proposed Order, # 2 Certification by Counsel to Be Admitted Pro Hac Vice - Dmitry V. Shelhoff, Esq., # 3 Certification by Counsel to Be Admitted Pro Hac Vice - Kenneth S. Canfield, Esq., # 4 Certification by Counsel to Be Admitted Pro Hac Vice - Edward D. Pergament, Esq., # 5 Certification by counsel to Be Admitted Pro Hac Vice - Julia S. Kim, Esq.)(Schladweiler, Benjamin) (Entered: 11/23/2022) (Certification by Counsel to Be Admitted Pro Hac Vice - Dmitry V. Shelhoff, Esq.) (1) |
| Nov 23, 2022 | 9 | MOTION for Pro Hac Vice Appearance of Attorney Dmitry v. Shelhoff, Kenneth S. Canfield, Edward D. Pergament and Julia S. Kim - filed by Zenara Pharma Private Limited. (Attachments: # 1 Text of Proposed Order Proposed Order, # 2 Certification by Counsel to Be Admitted Pro Hac Vice - Dmitry V. Shelhoff, Esq., # 3 Certification by Counsel to Be Admitted Pro Hac Vice - Kenneth S. Canfield, Esq., # 4 Certification by Counsel to Be Admitted Pro Hac Vice - Edward D. Pergament, Esq., # 5 Certification by counsel to Be Admitted Pro Hac Vice - Julia S. Kim, Esq.)(Schladweiler, Benjamin) (Entered: 11/23/2022) (Certification by Counsel to Be Admitted Pro Hac Vice - Kenneth S. Canfield, Esq) (1) |
| Nov 23, 2022 | 9 | MOTION for Pro Hac Vice Appearance of Attorney Dmitry v. Shelhoff, Kenneth S. Canfield, Edward D. Pergament and Julia S. Kim - filed by Zenara Pharma Private Limited. (Attachments: # 1 Text of Proposed Order Proposed Order, # 2 Certification by Counsel to Be Admitted Pro Hac Vice - Dmitry V. Shelhoff, Esq., # 3 Certification by Counsel to Be Admitted Pro Hac Vice - Kenneth S. Canfield, Esq., # 4 Certification by Counsel to Be Admitted Pro Hac Vice - Edward D. Pergament, Esq., # 5 Certification by counsel to Be Admitted Pro Hac Vice - Julia S. Kim, Esq.)(Schladweiler, Benjamin) (Entered: 11/23/2022) (Certification by Counsel to Be Admitted Pro Hac Vice - Edward D. Pergament, Esq) (1) |
| Nov 23, 2022 | 9 | MOTION for Pro Hac Vice Appearance of Attorney Dmitry v. Shelhoff, Kenneth S. Canfield, Edward D. Pergament and Julia S. Kim - filed by Zenara Pharma Private Limited. (Attachments: # 1 Text of Proposed Order Proposed Order, # 2 Certification by Counsel to Be Admitted Pro Hac Vice - Dmitry V. Shelhoff, Esq., # 3 Certification by Counsel to Be Admitted Pro Hac Vice - Kenneth S. Canfield, Esq., # 4 Certification by Counsel to Be Admitted Pro Hac Vice - Edward D. Pergament, Esq., # 5 Certification by counsel to Be Admitted Pro Hac Vice - Julia S. Kim, Esq.)(Schladweiler, Benjamin) (Entered: 11/23/2022) (Certification by counsel to Be Admitted Pro Hac Vice - Julia S. Kim, Esq.) (1) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Main Document) (30) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 1) (16) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 2) (8) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 3) (4) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 4) (3) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 5) (4) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 6) (8) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 7) (12) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 8) (4) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 9) (8) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 10) (14) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 11) (7) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 12) (7) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 13) (4) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 14) (8) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 15) (3) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 16) (12) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 17) (5) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 18) (5) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 19) (3) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 20) (8) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 21) (3) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 22) (3) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 23) (2) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 24) (3) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 25) (3) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 26) (2) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 27) (11) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 28) (4) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 29) (2) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 30) (4) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 31) (2) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Exhibit 32) (8) |
| Nov 18, 2022 | 8 | ANSWER to 1 Complaint and Additional Defenses by Zenara Pharma Private Limited. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28, # 29 Exhibit 29, # 30 Exhibit 30, # 31 Exhibit 31, # 32 Exhibit 32, # 33 Certificate of Service)(Schladweiler, Benjamin) Modified on 11/18/2022 (dlw). (Entered: 11/18/2022) (Certificate of Service) (1) |
| Sep 22, 2022 | 7 | WAIVER OF SERVICE returned executed by Intercept Pharmaceuticals, Inc., Intercept Pharma Europe Limited: For Zenara Pharma Private Limited waiver sent on 9/22/2022, answer due 11/21/2022. (Tigan, Jeremy) (Entered: 09/22/2022) (1) |
| Sep 16, 2022 | 1 | Complaint* (1) |
| Sep 16, 2022 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) (Entered: 09/19/2022) (3) |
| Sep 16, 2022 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 08/08/2022. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 2/8/2025. (mpb) (Entered: 09/19/2022) (1) |
| Sep 16, 2022 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,238,673 B2 ;10,047,117 B2 ;10,052,337 B2 ;10,174,073 B2 ;10,751,349 B2 ;10,758,549 B2. (mpb) (Entered: 09/19/2022) (2) |
| Sep 16, 2022 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Intercept Pharmaceuticals, Inc. for Intercept Pharma Europe Limited; filed by Intercept Pharma Europe Limited, Intercept Pharmaceuticals, Inc.. (mpb) (Entered: 09/19/2022) (2) |
| Sep 16, 2022 | 6 | Summons Issued as to Zenara Pharma Private Limited on 9/16/2022. (mpb) (Entered: 09/19/2022) (2) |
